Grants and Contracts
| PI | Name of Award Description of Study |
Project Start |
Project End |
Awarded By | Total Value |
| Ken Rosenman | MI COVID-19 Workers' Compensation Claims Analysis | 1/4/2021 | 9/30/2021 | CDC/NIH | $8,300 |
| Anthony Oliveri/ Melissa Millerick-May | COVID-19 Preparedness for Agricultural Operations in Michigan | 10/1/2020 | 9/30/2021 | MDHHS | $40,000 |
| Johnson/ Meghea | Meeting Women Where They Are: Multilevel intervention addressing racial disparities in maternal morbidity and mortality | 9/1/2020 | 8/30/2025 | NIH/NIMHD | $3,944,351 |
| Ken Rosenman/ Dawn Misra | COVID-19 Mortality Review | 8/1/2020 | 12/30/2020 | MDHHS | $88,372 |
| Adesuwa Olomu | Improving Diabetic Patients Adherence to Treatment and Prevention of Cardiovascular Disease | 7/15/2020 | 4/30/2025 | NIH | $3,891,123 |
| Ken Rosenman | Natural History of Chronic Beryllium Disease/beryllium Sensitization | 1/1/2020 | 12/31/2020 | Materion Corp | $139,274 |
| Ken Rosenman | Adult Blood Lead Epidemiology and Surveillance (ABLES) Program FY20 Master Agreement | 5/1/2020 | 9/30/2020 | MDHHS | $22,000 |
| Craig Cole | Phase I/II Open Label Dose escalation & expansion study to evaluate safety tolerability & clinical activity of the natibody drug Conjugate GSK2857916 adminstered in combination with Lenalidomide | TBD (due to COVID) | Glaxosmithkline | $6,000 | |
| Anthony Oliveri | Supporting Michigan Agriculture 2020 | 10/1/2019 | 9/30/2020 | MI Dept of Licensing & Regulatory Affairs | $35,000 |
| Borys Hrinczenko | Open label multicenter follow up study to collect long term data on partipants from Multiple Avelumab | 10/1/2019 | 9/30/2023 | EMD Serono Inc | $2,750 |
| Muhammad Nabeel | Patient Experience Research Study | 6/3/2019 | 6/2/2020 | Sparrow Foundation | $10,000 |
| Anthony Oliveri and Ken Rosenman | Child Lead Exposure Elimination Innovation Grant – 2019 - A statewide program to prevent child take-home lead exposures in Michigan | 6/1/2019 | 5/31/2020 | MI Dept of Health & Human Services | $133,536 |
| Ramakrishna Mukkamala Co-I: Supratik Rayamajhi and Ralph Watson | A Smartphone-Based Device for Cuff-Less and Calibration-Free Blood Pressure | 5/16/2019 | 5/15/2023 | National Inst of Health | $750,000 |
| Jatin Rana | A Phase II Double-Blinded Placebo Controlled Randomized Trial of Salvage Radiotherapy with or without enhanced anti-androgen therapy with apalutamide | 11/1/2018 | 10/31/2023 | NRG-NIH | Clinical Trial |
| Anthony Oliveri | Supporting MI Agriculture 2019-Implementing Respiratory Protection and Hazard Identification |
10/1/2018 | 9/30/2019 | State of MI | $19,999 |
| Jatin Rana | Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therap for patients with stage III colon cancer and deficient DNA mismatch repair | 10/1/2018 | 9/30/2023 | NRG-NCI | Clinical Trial |
| Borys Hrinczenko | Randomized Double Blind Placebo Controlled Pilot Study of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced Nonsmall cell Lung Cancer | 9/1/2018 | 8/31/2024 | NRG-NCI | Clinical Trial |
| Jatin Rana | Phase 3 Newly Diagnosed Symptomatic Multiple Myeloma | 8/1/2018 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Jatin Rana | Phase 3 Her 2 Negative Advance/Metastatic Breast Cancer | 7/3/2018 | 7/21/2023 | BIG Ten Cancer Consortium | Clinical Trial |
| Ken Rosenman | Evaluation of Silicosis, Asthma & COPD amount sand/gravel & Stone Surface Miners |
7/1/2018 | 12/31/2019 | Alpha Foundation for the Improvement of Mine Safety & Health Inc |
$250,000 |
| Ken Rosenman | Worksite intervention to Mitigate Child Take Home Lead Exposure | 6/1/2018 | 5/31/2019 | MI Dept of Health & Human Services | $75,000 |
| Jatin Rana | Phase 3 Evaluating the role of weight loss in adjuvant treatment of overweight/obese women with early breast cancer | 6/1/2018 | 5/31/2023 | NRG - NCI/NIH | Clinical Trial |
| MSU Breslin Cancer Center | Phase 3 Newly Diagnosed Acute Myeloid Leukemia unfit for standard chemotherapy | 4/2/2018 | 4/30/2023 | Helsinn HealthCare/MEI Pharma, INC | Clinical Trial |
| Ralph Watson | Epigenomics of Hypertension in Monozygotic Twins & effect of salt intake |
4/1/2018 | 3/31/2019 | American Heart Assoc | $109,658 |
| Jatin Rana | Phase 1/2 Advance AR + Triple Negative Breast Cancer | 3/23/2018 | 3/31/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Jatin Rana | Phase2 Metastatic or Advance Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma | 11/20/2017 | 11/30/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Borys Hrinczenko | Phase 2 Non-small Cell Lung Cancer | 11/13/2017 | 11/30/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| MSU Breslin Cancer Center | Phase 3 Neoadjuvant Chemotherapy with Triple Negative Breast Cancer | 11/1/2017 | 1/31/2023 | NSABP | Clinical Trial |
| Jatin Rana | Phase 2 Unresponsive Non-Muscle Invasive Bladder Cancer | 9/29/2017 | 9/28/2022 | NRG - NCI/NIH | Clinical Trial |
| Jatin Rana | Phase 2 High Risk Myelodysplastic Syndrome | 8/15/2017 | 7/31/2022 | Helsinn HealthCare/MEI Pharma, INC | Clinical Trial |
| Jatin Rana | Phase 2/3 Replapsed or Refractory Multiple Myeloma | 8/1/2017 | 7/31/2022 | Millennium Pharmaceutical | Clinical Trial |
| Jatin Rana | The National Myelodysplastic Syndromes (MDS) Study | 5/30/2017 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Borys Hrinczenko | Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetasel or Pemetrexed Alone in Patients with Herebulin Positive Locally Advanced or Metastatic Non-small cell lung | 5/1/2017 | 4/30/2021 | Merrimack Pharmaceuticals | Clinical Trial |
| Jatin Rana | Phase 3 Triple Receptor Negative Breast Cancer with>1cm residual invasive cancer or positive lymph nodes | 5/1/2017 | 12/31/2019 | NRG - NCI SWOG | Clinical Trial |
| Borys Hrinczenko | Prospective, Lognitudinal Non-Interventional study for patients with low risk Myelofibrosis | 2/2/2017 | 1/29/2022 | Incyte Pharmaceutical | Clinical Trial |
| MSU Breslin Cancer Center | Phase 1/2 Relapsed or Refractory Diffuse Large B Cell Lymphoma | 1/5/2017 | 1/5/2020 | Incyte Pharmaceutical | Clinical Trial |
| Melissa Millerick May | Improved method for identifying Causative Antigen in Hypersensitivity Pheumonitis |
12/1/2016 | 11/30/2021 | National Inst of Allergy & Infectious Diseases | $978,194 |
| MSU Breslin Cancer Center | Molecular Analysis for Therapy Choice (MATCH) | 10/3/2016 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Jatin Rana | Phase 2 Metastatic Hormone Receptor Positive Breast Cancer | 9/8/2016 | 7/31/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Ken Rosenman | Worker Compensation Surveillance | 9/1/2016 | 8/31/2019 | National Inst of Health | $600,000 |
| Borys Hrinczenko | Phase 2 Esophageal Cancer | 8/26/2016 | 7/31/2019 | BIG Ten Cancer Consortium | Clinical Trial |
| Borys Hrinczenko | Phase 3 Stage 3 Colon Cancer | 7/1/2016 | 6/30/2020 | NRG - NCI/NIH | Clinical Trial |
| Jatin Rana | Phase 3 High Risk Hormone Receptor-Positive, HER2 Negative Breast Cancer | 6/1/2016 | 2/28/2019 | NRG - NIH SWOG | Clinical Trial |
| Jatin Rana | Phase 3 BRCA1/2, High Risk HER2 Negative Breast Cancer | 6/1/2016 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Borys Hrinczenko | Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subject | 4/20/2016 | 12/31/2019 | EMD Serono Inc | Clinical Trial |
| Elahe Crockett-Torabi | Research Education Program to increase diversity in health related research | 4/1/2016 | 3/31/2021 | National Inst of Health | $798,243 |
| Ken Rosenman | Expanded Program in Occupational Injury & Illness Surveillance | 7/1/2015 | 6/30/2020 | Centers for Disease Control & Prevention | $3,575,967 |
| Melissa Millerick May | A field based investigation of the generation of bioaerosol containing Porcine Epidemic Diarrhea virus (PEDv) during manure removals on swine farms in Michigan |
4/16/2015 | 8/31/2019 | Michigan Pork Producers Assoc | $10,500 |
| Borys Hrinczenko | A phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metasta | 2/26/2014 | 12/31/2019 | EMD Serono Inc | Clinical Trial |